Your session is about to expire
← Back to Search
Levetiracetam for Schizophrenia
Study Summary
This trial will study the effects of LEV on brain activity and cognition in people with schizophrenia or schizoaffective disorder.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2006 Phase 4 trial • 251 Patients • NCT00160654Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have recently experienced a serious head injury.I have been diagnosed with schizophrenia or schizoaffective disorder.You have major problems with your brain or nervous system.You have a history of drug or alcohol abuse.I am in good health overall.
- Group 1: Placebo, Then Levetiracetam
- Group 2: Levetiracetam, Then Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional research has been conducted on the efficacy of Levetiracetam?
"Currently, 18 clinical trials are in progress for Levetiracetam. 2 of these active studies have reached Phase 3 development. While the majority of research is based out of Brisbane, Queensland; a total of 40 sites are running experiments involving this medication."
Are elderly individuals over the age of seventy-five eligible for this research endeavor?
"This research is open to individuals who are above the age of consent and younger than 65 years old."
Is there an eligibility criteria for accessing this experimental program?
"This clinical research is searching for 50 people diagnosed with schizophrenia between the ages of 18 and 65 to participate in their trial."
What conditions is Levetiracetam typically administered to address?
"Levetiracetam is routinely prescribed to treat juvenile myoclonic epilepsy and has been successfully used for other disorders like excessive body weight, epilepsies, and myoclonic seizures."
How extensive is the participant intake for this research study?
"That is correct, the trial is indeed seeking out participants. As per information available on clinicaltrials.gov, this study was initiated in September 2018 and last updated October 6th 2022; with a target of 50 individuals at one medical centre."
Is the intake of participants ongoing for this experiment?
"As per clinicaltrials.gov, this experiment is still actively recruiting participants. It was originally posted on September 1st 2018 and modified most recently on October 6th 2022."
Share this study with friends
Copy Link
Messenger